Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subject's parents or legal guardians must provide written informed consent prior to any study-related procedures.~* Documented onset of Pompe disease symptoms up to 12 months of age (corrected for gestation if born before 40 weeks); diagnosis of Pompe disease confirmed by acid alpha-glucosidase enzyme deficiency from any tissue source and acid alpha-glucosidase gene mutations.~* Age 0-12 months at enrollment, defined as at the time of providing written informed consent.~* Cardiomyopathy (abnormal left ventricular mass indices \[LVMIs\], measured by echocardiography, abnormal value is defined as ≥65 g/m2 for patients up to 12 months old) confirmed by cardiologist at study site.~Exclusion criteria:~* Patient who has previously been treated with acid alpha-glucosidase.~* Patient who is participating in another clinical study using any investigational therapy.~* Conditions/situations such as:~* Clinical signs of cardiac failure with ejection fraction \< 40%.~* Respiratory insufficiency (oxygen saturation \< 90% or carbon dioxide partial pressure \> 55 mm Hg \[venous\] or \> 40 mm hydrargyrum \[arterial\] in room air or any ventilator use).~* Patients who are dependent on invasive or non-invasive ventilator support.~* Patients with major congenital anomaly or clinically significant intercurrent organic disease unrelated to Pompe disease.~* Patients not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Alglucosidase Alfa therapy (Type: EXPERIMENTAL): Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).